Display options
Cite
Zeidan AM, Ridinger M, Lin TL, et al. A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia. Clin Cancer Res. 2020;26(23):6132-6140doi: 10.1158/1078-0432.CCR-20-2586.
Zeidan, A. M., Ridinger, M., Lin, T. L., Becker, P. S., Schiller, G. J., Patel, P. A., Spira, A. I., Tsai, M. L., Samuëlsz, E., Silberman, S. L., Erlander, M., & Wang, E. S. (2020). A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research, 26(23), 6132-6140. https://doi.org/10.1158/1078-0432.CCR-20-2586
Zeidan, Amer M, et al. "A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 26,23 (2020): 6132-6140. doi: https://doi.org/10.1158/1078-0432.CCR-20-2586
Zeidan AM, Ridinger M, Lin TL, Becker PS, Schiller GJ, Patel PA, Spira AI, Tsai ML, Samuëlsz E, Silberman SL, Erlander M, Wang ES. A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia. Clin Cancer Res. 2020 Dec 01;26(23):6132-6140. doi: 10.1158/1078-0432.CCR-20-2586. Epub 2020 Sep 30. PMID: 32998961.
Copy Download .nbib Format: NLM
Share it on

Clin Cancer Res. 2020 Dec 01;26(23):6132-6140. doi: 10.1158/1078-0432.CCR-20-2586. Epub 2020 Sep 30.

A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia.

Clinical cancer research : an official journal of the American Association for Cancer Research

Amer M Zeidan, Maya Ridinger, Tara L Lin, Pamela S Becker, Gary J Schiller, Prapti A Patel, Alexander I Spira, Michaela L Tsai, Errin Samuëlsz, Sandra L Silberman, Mark Erlander, Eunice S Wang

Affiliations

  1. Yale University and Yale Cancer Center, New Haven, Connecticut. [email protected].
  2. Cardiff Oncology, San Diego, California.
  3. Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas, Kansas City, Kansas.
  4. Division of Hematology, Department of Medicine, University of Washington and Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  5. Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.
  6. University Hospital Bone Marrow Transplant Clinic, Dallas, Texas.
  7. Virginia Cancer Specialists, Fairfax, Virginia.
  8. Minnesota Oncology, Minneapolis, Minnesota.
  9. SLS Oncology LLC, Durham, North Carolina.
  10. Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

PMID: 32998961 DOI: 10.1158/1078-0432.CCR-20-2586

Abstract

PURPOSE: The Polo-like kinase 1 (PLK1) is a master regulator of mitosis and overexpressed in acute myeloid leukemia (AML). We conducted a phase Ib study of the PLK1 inhibitor, onvansertib, in combination with either low-dose cytarabine (LDAC) or decitabine in patients with relapsed or refractory (R/R) AML.

PATIENTS AND METHODS: Onvansertib was administered orally, in escalating doses, on days 1-5 in combination with either LDAC (20 mg/m

RESULTS: Forty patients were treated with onvansertib (12-90 mg/m

CONCLUSIONS: The onvansertib and decitabine combination was well tolerated and had antileukemic activity particularly in patients with target engagement and decreased mutant ctDNA following treatment. This combination will be further investigated in the ongoing phase II trial.

©2020 American Association for Cancer Research.

References

  1. Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019;36:70–87. - PubMed
  2. Wang ES. Treating acute myeloid leukemia in older adults. Hematology Am Soc Hematol Educ Program. 2014;2014:14–20. - PubMed
  3. DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7–17. - PubMed
  4. Wei AH, Strickland SA, Hou J-Z, Fiedler W, Lin TL, Walter RB, et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study. J Clin Oncol. 2019;37:1277–84. - PubMed
  5. Norsworthy KJ, By K, Subramaniam S, Zhuang L, Del Valle PL, Przepiorka D, et al. FDA approval summary: glasdegib for newly diagnosed acute myeloid leukemia. Clin Cancer Res. 2019;25:6021–5. - PubMed
  6. DiNardo CD, Jonas BA, Pullarkat V, Thirman M, Garcia J, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617–29. - PubMed
  7. Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135:2137–45. - PubMed
  8. Ferrara F, Lessi F, Vitagliano O, Birkenghi E, Rossi G. Current therapeutic results and treatment options for older patients with relapsed acute myeloid leukemia. Cancers. 2019;11:224. - PubMed
  9. Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, et al. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica. 2020 Jun 4. - PubMed
  10. Barr FA, Silljé HHW, Nigg EA. Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol. 2004;5:429–40. - PubMed
  11. Degenhardt Y, Lampkin T. Targeting polo-like kinase in cancer therapy. Clin Cancer Res. 2010;16:384–9. - PubMed
  12. Renner AG, Dos Santos C, Recher C, Bailly C, Créancier L, Kruczynski A, et al. Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells. Blood. 2009;114:659–62. - PubMed
  13. Gutteridge REA, Ndiaye MA, Liu X, Ahmad N. Plk1 inhibitors in cancer therapy: from laboratory to clinics. Mol Cancer Ther. 2016;15:1427–35. - PubMed
  14. Döhner H, Lübbert M, Fiedler W, Fouillard L, Haaland A, Brandwein JM, et al. Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. Blood. 2014;124:1426–33. - PubMed
  15. Döhner H, Symeonidis A, Sanz A, Deeren D, Demeter J, Anagnostopoulos A, et al. Phase III randomized trial of volasertib plus low-dose cytarabine (LDAC) versus placebo plus LDAC in patients aged ≥65 years with previously untreated AML, ineligible for intensive therapy. Haematologica. 2016;101:1–881. - PubMed
  16. Valsasina B, Beria I, Alli C, Alzani R, Avanzi N, Ballinari D, et al. NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies. Mol Cancer Ther. 2012;11:1006–16. - PubMed
  17. Casolaro A, Golay J, Albanese C, Ceruti R, Patton V, Cribioli S, et al. The Polo-like kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia. PLoS One. 2013;8:e58424. - PubMed
  18. Weiss GJ, Jameson G, Von Hoff DD, Valsasina B, Davite C, Di Giulio C, et al. Phase I dose escalation study of NMS-1286937, an orally available Polo-like kinase 1 inhibitor, in patients with advanced or metastatic solid tumors. Invest New Drugs. 2018;36:85–95. - PubMed
  19. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21:4642–9. - PubMed
  20. Levis M, Brown P, Smith BD, Stine A, Pham R, Stone R, et al. Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood. 2006;108:3477–83. - PubMed
  21. Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3:32–5. - PubMed
  22. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77. - PubMed
  23. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47. - PubMed
  24. Yeh P, Dickinson M, Ftouni S, Hunter T, Sinha D, Wong SQ, et al. Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes. Blood. 2017;129:1685–90. - PubMed
  25. Nakamura S, Yokoyama K, Shimizu E, Yusa N, Kondoh K, Ogawa M, et al. Prognostic impact of circulating tumor DNA status post–allogeneic hematopoietic stem cell transplantation in AML and MDS. Blood. 2019;133:2682–95. - PubMed
  26. Cucchi U, Gianellini LM, De Ponti A, Sola F, Alzani R, Patton V, et al. Phosphorylation of TCTP as a marker for polo-like kinase-1 activity in vivo. Anticancer Res. 2010;30:4973–85. - PubMed
  27. Goroshchuk O, Kolosenko I, Vidarsdottir L, Azimi A, Palm-Apergi C. Polo-like kinases and acute leukemia. Oncogene. 2019;38:1–16. - PubMed
  28. Strebhardt K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov. 2010;9:643–60. - PubMed
  29. Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, et al. Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. Blood Adv. 2018;2:923–32. - PubMed

Publication Types